PMID- 21696824
OWN - NLM
STAT- MEDLINE
DCOM- 20111123
LR  - 20171116
IS  - 1873-5835 (Electronic)
IS  - 0145-2126 (Linking)
VI  - 35
IP  - 10
DP  - 2011 Oct
TI  - HLA-G expression is irrelevant to prognosis in patients with acute myeloid 
      leukemia.
PG  - 1350-4
LID - 10.1016/j.leukres.2011.05.036 [doi]
AB  - Human leukocyte antigen (HLA)-G could contribute to escape of cancer cells from 
      host anti-tumor responses, and its potential clinical relevance in various 
      malignancies was also addressed. However, the prognostic value of HLA-G in acute 
      myeloid leukemia (AML) remains debated. In this study, HLA-G expression in 
      malignant blasts was analyzed from 77 de novo AML patients (AML-M2, n=26; AML-M3, 
      n=24; AML-M4, n=10; AML-M5, n=17) with flow cytometry. The proportion of HLA-G 
      expressing blasts varied from 0% to 93.96% (median: 0.42%; 95% CI: 0-89.0%). 
      Blasts with 0.5% or fewer HLA-G expressing were defined as negative according to 
      its expression in normal CD34(+)CD45(+) cells (n=20, range: 0-0.5%; median: 
      0.13%; 95% CI: 0-0.42%). HLA-G expression status on leukemic blasts was not 
      associated with the clinical parameters such as patient age at diagnosis, sex, 
      sub-type of AML, percentage of blasts at diagnosis. Survival analysis revealed 
      that HLA-G expression status on leukemic blasts is unrelated to the prognosis 
      (p=0.884). The mean overall survival time for the HLA-G negative and positive 
      patients was 20.7 months (95% CI: 16.1-25.3) and 20.1 months (95% CI: 14.3-25.8), 
      respectively. Taken together, our findings indicated that HLA-G expression is of 
      no significance for the prognosis of patients with AML.
CI  - Copyright (c) 2011 Elsevier Ltd. All rights reserved.
FAU - Guo, Q Y
AU  - Guo QY
AD  - Department of Hematology, Taizhou Hospital of Zhejiang Province, Wenzhou Medical 
      College, Linhai, Zhejiang, China.
FAU - Chen, B G
AU  - Chen BG
FAU - Ruan, Y Y
AU  - Ruan YY
FAU - Lin, A
AU  - Lin A
FAU - Yan, W H
AU  - Yan WH
LA  - eng
PT  - Journal Article
DEP - 20110621
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - 0 (Antigens, CD34)
RN  - 0 (HLA-G Antigens)
RN  - EC 3.1.3.48 (Leukocyte Common Antigens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, CD34/*biosynthesis/immunology
MH  - Child
MH  - Female
MH  - Flow Cytometry
MH  - Gene Expression
MH  - *HLA-G Antigens/analysis/genetics/immunology
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*diagnosis/genetics/immunology/mortality/pathology
MH  - Leukocyte Common Antigens/*biosynthesis/immunology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Sex Factors
MH  - Survival Analysis
MH  - T-Lymphocytes/*immunology/pathology
EDAT- 2011/06/24 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/06/24 06:00
PHST- 2011/01/24 00:00 [received]
PHST- 2011/04/14 00:00 [revised]
PHST- 2011/05/29 00:00 [accepted]
PHST- 2011/06/24 06:00 [entrez]
PHST- 2011/06/24 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - S0145-2126(11)00271-2 [pii]
AID - 10.1016/j.leukres.2011.05.036 [doi]
PST - ppublish
SO  - Leuk Res. 2011 Oct;35(10):1350-4. doi: 10.1016/j.leukres.2011.05.036. Epub 2011 
      Jun 21.